

Ideaya Biosciences, Inc. (IDYA)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001676725

Ideaya Biosciences, Inc.	
IDYA; healthcare	
Grade	A strongest fifth of 371 graded peers percentile 4.3; sampling error 2.5 points; lower is stronger
Rank	17 of 371
Profitability	D percentile 67.5
Solvency	A percentile 11.4
Growth and financing	A percentile 11.8
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$1.1B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 17, 2026 234 days before the rescans; latest periodic filing 10-Q received Aug 4, 2026
Last close	\$36.06 2026-10-08; market equity \$3.5B
Price used in grade	None

A, the bull
strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it

Rescans on file: A from Aug 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

[illegible]

Business, in the company's words

opening of Item 1 of the 10-K received Feb 17, 2026

We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality

and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 67.5						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(3.8%)	(6.6%)	67.5	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 11.4						
Twelve-month failure probability		0.03%	0.07%	14.2	248	2026-06-30
Altman Z double-prime		12.90	(0.31)	6.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		11.34x	2.96x	13.5	839	2025-12-31
Growth and financing, sleeve percentile 11.8						
Revenue growth, three-year compound		62.5%	10.0%	9.4	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		41.9%	2.1%	10.0	704	2025-12-31
Net share issuance, one year		0.3%	2.5%	16.0	634	2026-02-13

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
12	Penumbra Inc. (PEN)	3.0	A	
13	Lemaitre Vascular Inc. (LMAT)	3.2	A	
14	Corcept Therapeutics Inc. (CORT)	3.5	A	fortress
				balance sheet
15	Electromed, Inc. (ELMD)	3.8	A	fortress
				balance sheet
16	Tactile Systems Technology Inc. (TCMD)	4.1	A	fortress
				balance sheet
17	Ideaya Biosciences, Inc. (IDYA) <	4.3	A	
18	Vericel Corp. (VCEL)	4.6	A	
19	Tarsus Pharmaceuticals, Inc. (TARS)	4.9	A	fortress
				balance sheet
20	Biomarin Pharmaceutical Inc. (BMRN)	5.1	A	
21	Neurocrine Biosciences Inc. (NBIX)	5.4	A	
22	Crispr Therapeutics AG (CRSP)	5.7	A	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	47.4%	8.0%	75
Distance from 52-week high	(15.1%)	(31.4%)	73
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(2.1%)	(1.0%)	47
Book value to price	0.34	0.28	57
Sales to price	0.06	0.31	19
Composite equity issuance, five years	109.6%	20.3%	80
Relative strength against the sector, log excess return	0.18	(0.14)	75

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$272.6M
Operating cash flow, four quarters	-\$111.7M

Months of runway	29.3
Days since last periodic filing	66 (10-Q received Aug 4, 2026)
Median daily dollar volume, 63 sessions	\$25.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$113.7M	2025-12-31	2026-02-17	10-K	0001193125-26-054533
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$71.1M	2025-12-31	2026-02-17	10-K	0001193125-26-054533
3	assets	us-gaap:Assets	\$1.1B	2025-12-31	2026-02-17	10-K	0001193125-26-054533
4	assets	us-gaap:Assets	\$1.1B	2024-12-31	2026-02-17	10-K	0001193125-26-054533
5	current assets	us-gaap:AssetsCurrent	\$666.7M	2025-12-31	2026-02-17	10-K	0001193125-26-054533
6	current liabilities	us-gaap:LiabilitiesCurrent	\$58.8M	2025-12-31	2026-02-17	10-K	0001193125-26-054533
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$736.5M	2025-12-31	2026-02-17	10-K	0001193125-26-054533
8	operating income	us-gaap:OperatingIncomeLoss	-\$159.3M	2025-12-31	2026-02-17	10-K	0001193125-26-054533
9	book equity	us-gaap:StockholdersEquity	\$1.0B	2025-12-31	2026-02-17	10-K	0001193125-26-054533
10	liabilities	us-gaap:Liabilities	\$86.4M	2025-12-31	2026-02-17	10-K	0001193125-26-054533
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$218.7M	2025-12-31	2026-02-17	10-K	0001193125-26-054533
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$7.0M	2024-12-31	2026-02-17	10-K	0001193125-26-054533
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$23.4M	2023-12-31	2026-02-17	10-K	0001193125-26-054533
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$50.9M	2022-12-31	2025-02-18	10-K	0000950170-25-022183
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.4M	2025-12-31	2026-02-17	10-K	0001193125-26-054533
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$247.6M	2024-12-31	2026-02-17	10-K	0001193125-26-054533
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.9M	2024-12-31	2026-02-17	10-K	0001193125-26-054533
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$115.2M	2023-12-31	2026-02-17	10-K	0001193125-26-054533
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.4M	2023-12-31	2026-02-17	10-K	0001193125-26-054533
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$87.2M	2022-12-31	2025-02-18	10-K	0000950170-25-022183
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.4M	2022-12-31	2025-02-18	10-K	0000950170-25-022183
22	assets	us-gaap:Assets	\$649.3M	2023-12-31	2025-02-18	10-K	0000950170-25-022183
23	assets	us-gaap:Assets	\$388.0M	2022-12-31	2024-02-20	10-K	0000950170-24-017093
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	87,814,027	2026-02-13	2026-02-17	10-K	0001193125-26-054533
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	87,537,391	2025-02-14	2025-02-18	10-K	0000950170-25-022183